Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
6.11
+0.01 (0.16%)
Aug 10, 2026, 11:25 AM EDT - Market open

Wave Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
65.3742.73108.3113.313.6540.96
Revenue Growth
-30.42%-60.55%-4.42%3005.10%-91.09%104.03%
Gross Profit
65.3742.73108.3113.313.6540.96
Selling, General & Admin
85.8775.3359.0251.2950.5146.11
Research & Development
197.42182.78159.68130.01115.86121.88
Total Operating Expenses
283.29258.11218.71181.3166.37167.98
Operating Income
-217.92-215.38-110.4-68-162.72-127.02
Interest Income
12.1910.4810.167.931.570.03
Other Non-Operating Income (Expense)
0.20.533.231.880.014.54
Total Non-Operating Income (Expense)
15.4511.0113.49.811.584.57
Pretax Income
-202.47-204.38-97.01-58.19-161.14-122.45
Net Income
-202.47-204.38-97.01-57.51-161.82-122.25
Net Income to Common
-202.47-204.38-97.01-57.51-161.82-122.25
Net Income Growth
------
Shares Outstanding (Basic)
1881691381067952
Shares Outstanding (Diluted)
1881691381067952
Shares Change
19.11%21.96%30.33%34.55%52.16%32.12%
EPS (Basic)
-1.09-1.21-0.70-0.54-2.05-2.36
EPS (Diluted)
-1.09-1.21-0.70-0.54-2.05-2.36
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-193.15-188.21-151.96-20.55-129.14-89.55
Free Cash Flow Growth
------
Free Cash Flow Per Share
-1.03-1.12-1.10-0.19-1.64-1.73
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-333.36%-504.09%-101.94%-60.01%-4459.30%-310.07%
Profit Margin
-309.73%-478.34%-89.57%-50.76%-4434.72%-298.42%
FCF Margin
-295.46%-440.50%-140.31%-18.13%-3539.11%-218.61%
EBITDA
-214.52-211.94-106.51-63-156.15-119.53
EBITDA Margin
-328.16%-496.04%-98.34%-55.60%-4279.14%-291.80%
EBIT
-217.92-215.38-110.4-68-162.72-127.02
EBIT Margin
-333.36%-504.09%-101.94%-60.01%-4459.30%-310.07%
SEC Filings: 10-K · 10-Q